1. Home
  2. MLYS vs MCB Comparison

MLYS vs MCB Comparison

Compare MLYS & MCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • MCB
  • Stock Information
  • Founded
  • MLYS 2019
  • MCB 1999
  • Country
  • MLYS United States
  • MCB United States
  • Employees
  • MLYS N/A
  • MCB N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • MCB Major Banks
  • Sector
  • MLYS Health Care
  • MCB Finance
  • Exchange
  • MLYS Nasdaq
  • MCB Nasdaq
  • Market Cap
  • MLYS 590.3M
  • MCB 567.0M
  • IPO Year
  • MLYS 2023
  • MCB 2017
  • Fundamental
  • Price
  • MLYS $13.88
  • MCB $53.79
  • Analyst Decision
  • MLYS Strong Buy
  • MCB Buy
  • Analyst Count
  • MLYS 2
  • MCB 4
  • Target Price
  • MLYS $30.00
  • MCB $63.13
  • AVG Volume (30 Days)
  • MLYS 122.0K
  • MCB 74.4K
  • Earning Date
  • MLYS 11-05-2024
  • MCB 10-17-2024
  • Dividend Yield
  • MLYS N/A
  • MCB N/A
  • EPS Growth
  • MLYS N/A
  • MCB 22.09
  • EPS
  • MLYS N/A
  • MCB 6.26
  • Revenue
  • MLYS N/A
  • MCB $248,618,000.00
  • Revenue This Year
  • MLYS N/A
  • MCB N/A
  • Revenue Next Year
  • MLYS N/A
  • MCB $7.32
  • P/E Ratio
  • MLYS N/A
  • MCB $8.61
  • Revenue Growth
  • MLYS N/A
  • MCB N/A
  • 52 Week Low
  • MLYS $5.85
  • MCB $30.20
  • 52 Week High
  • MLYS $16.91
  • MCB $57.69
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 70.82
  • MCB 59.29
  • Support Level
  • MLYS $11.73
  • MCB $49.35
  • Resistance Level
  • MLYS $12.27
  • MCB $52.75
  • Average True Range (ATR)
  • MLYS 0.61
  • MCB 2.09
  • MACD
  • MLYS 0.19
  • MCB 0.10
  • Stochastic Oscillator
  • MLYS 98.50
  • MCB 69.92

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

About MCB Metropolitan Bank Holding Corp.

Metropolitan Bank Holding Corp is a bank holding company. It provides a broad range of business, commercial, and retail banking products and services to small businesses, middle-market enterprises, public entities, and individuals in the New York metropolitan area. The services provided by the company include deposits, trade finance, cash management solutions, savings, electronic banking, cards, and others. The company also provides various lending products such as acquisition loans, construction loans, and lines of credit, for retail, office, hospitality, multifamily, mixed-use, warehouse and distribution, and specialty-use properties. The bank derives its revenue in the form of interest income on loans.

Share on Social Networks: